Scholarlink

Purpose <p>This study aimed to evaluate the impact of azacitidine (AZA) combined with venetoclax (VEN) compared to AZA monotherapy on systemic inflammatory markers and the overall response rate (ORR) in elderly patients with newly-diagnosed acute myeloid leukemia (AML) who were unfit for intensive chemotherapy.</p> Methods <p>A retrospective cohort study included 205 patients (≥ 60 years) treated between January 2021 and June 2022. Patients received either AZA alone (<i>n</i> = 93) or AZA plus VEN (<i>n</i> = 112). Serum levels of C-reactive protein (CRP), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-α) were measured at baseline and after three treatment cycles. ORR was assessed using International Working Group criteria.</p> Results <p>The combination therapy group showed significantly greater reductions in inflammatory markers (CRP, IL-6, TNF-α; all <i>P</i> &lt; 0.001) and improved hematological recovery compared to monotherapy. ORR was higher with combination therapy (73.21% vs. 46.24%, <i>P</i> &lt; 0.001). Baseline TNF-α &gt; 70 pg/mL was independently associated with lower ORR (OR 0.589, <i>P</i> = 0.016). The incidence of adverse events did not differ significantly between groups.</p> Conclusion <p>AZA plus VEN was associated with significantly greater reductions in systemic inflammation and improved treatment responses compared to AZA monotherapy in elderly AML patients, without a significant increase in severe toxicity. These findings suggest that the combination regimen may be a promising first-line option for this population; however, prospective randomized trials are warranted to confirm these observations.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Effects of azacitidine combined with venetoclax on inflammatory markers and overall response rate in elderly patients with newly diagnosed acute myeloid leukemia

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年7月27日

查看全文
  • Hui-Fang Liu,
  • Cheng Lian,
  • Xian-Guang Zhu

摘要

Purpose

This study aimed to evaluate the impact of azacitidine (AZA) combined with venetoclax (VEN) compared to AZA monotherapy on systemic inflammatory markers and the overall response rate (ORR) in elderly patients with newly-diagnosed acute myeloid leukemia (AML) who were unfit for intensive chemotherapy.

Methods

A retrospective cohort study included 205 patients (≥ 60 years) treated between January 2021 and June 2022. Patients received either AZA alone (n = 93) or AZA plus VEN (n = 112). Serum levels of C-reactive protein (CRP), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-α) were measured at baseline and after three treatment cycles. ORR was assessed using International Working Group criteria.

Results

The combination therapy group showed significantly greater reductions in inflammatory markers (CRP, IL-6, TNF-α; all P < 0.001) and improved hematological recovery compared to monotherapy. ORR was higher with combination therapy (73.21% vs. 46.24%, P < 0.001). Baseline TNF-α > 70 pg/mL was independently associated with lower ORR (OR 0.589, P = 0.016). The incidence of adverse events did not differ significantly between groups.

Conclusion

AZA plus VEN was associated with significantly greater reductions in systemic inflammation and improved treatment responses compared to AZA monotherapy in elderly AML patients, without a significant increase in severe toxicity. These findings suggest that the combination regimen may be a promising first-line option for this population; however, prospective randomized trials are warranted to confirm these observations.